Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
For the six months, net income was USD 0.38 million compared to net loss of USD 0.504 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.02 a year ago. Diluted loss per share from continuing operations was USD 0.01 compared to USD 0.02 a year ago.